CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2585949&ei=knKaUrDjLa210AHc1AE&usg=AFQjCNFKjWtdM-KHFe_F_wLViDg0-zBGeQ
Celgene Corporation Prices $1.5 Billion of Senior Unsecured Notes
Tuesday, 7 Aug 2012 08:15am EDT
Celgene Corporation announced the pricing of two series of senior unsecured notes for an aggregate principal amount of $1.5 billion. Of these notes, $500 million will mature in 2017 and will bear interest at an annual rate of 1.900%, and $1 billion will mature in 2022 and will bear interest at an annual rate of 3.250%. The 1.900% notes due 2017, and the 3.250% notes due 2022 were priced to yield 1.945% and 3.256%, respectively. Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene’s clinical and pre-clinical programs, capital expenditures, general corporate development activities and meeting working capital needs. The offering is expected to close on August 9, 2012. BofA Merrill Lynch, J.P. Morgan, and Morgan Stanley are acting as joint book-running managers. 
